PRELUDE THERAPEUTICS INC (PRLD) Stock Price & Overview
NASDAQ:PRLD • US74065P1012
The current stock price of PRLD is 3.81 USD. Today PRLD is up by 5.83%. In the past month the price increased by 81.43%. In the past year, price increased by 411.55%.
PRLD Key Statistics
- Market Cap
- 239.535M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.47
- Dividend Yield
- N/A
PRLD Stock Performance
PRLD Stock Chart
PRLD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PRLD. When comparing the yearly performance of all stocks, PRLD is one of the better performing stocks in the market, outperforming 99.21% of all stocks.
PRLD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRLD. The financial health of PRLD is average, but there are quite some concerns on its profitability.
PRLD Earnings
On November 12, 2025 PRLD reported an EPS of -0.26 and a revenue of 6.50M. The company beat EPS expectations (30.21% surprise).
PRLD Forecast & Estimates
9 analysts have analysed PRLD and the average price target is 4.08 USD. This implies a price increase of 7.09% is expected in the next year compared to the current price of 3.81.
For the next year, analysts expect an EPS growth of 24.65% and a revenue growth -100% for PRLD
PRLD Groups
Sector & Classification
PRLD Financial Highlights
Over the last trailing twelve months PRLD reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS increased by 16.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -134.21% | ||
| ROE | -217.26% | ||
| Debt/Equity | 0 |
PRLD Ownership
PRLD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.34 | 401.392B | ||
| AMGN | AMGEN INC | 16.55 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.52 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.4 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.57 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.95 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.85 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.24 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340.18 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PRLD
Company Profile
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Company Info
IPO: 2020-09-25
PRELUDE THERAPEUTICS INC
175 Innovation Boulevard
Wilmington DELAWARE 19803 US
CEO: Krishna Vaddi
Employees: 131
Phone: 13026589200
PRELUDE THERAPEUTICS INC / PRLD FAQ
What does PRLD do?
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
What is the current price of PRLD stock?
The current stock price of PRLD is 3.81 USD. The price increased by 5.83% in the last trading session.
Does PRLD stock pay dividends?
PRLD does not pay a dividend.
How is the ChartMill rating for PRELUDE THERAPEUTICS INC?
PRLD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for PRLD stock?
PRELUDE THERAPEUTICS INC (PRLD) currently has 131 employees.
When does PRELUDE THERAPEUTICS INC (PRLD) report earnings?
PRELUDE THERAPEUTICS INC (PRLD) will report earnings on 2026-03-18, after the market close.
What is the ownership structure of PRELUDE THERAPEUTICS INC (PRLD)?
You can find the ownership structure of PRELUDE THERAPEUTICS INC (PRLD) on the Ownership tab.